This is of clinical interest since treatment of advanced BC is historically based on the HER2 status of the primary tumor and several studies have suggested a possible clinically significant discordance of up to 42% between the HER2 status at primary and later disease stages [13, 14]. Here, ERBB2 is linked to neoplasm.